Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.

Martínez-Vélez N, Garcia-Moure M, Marigil M, González-Huarriz M, Puigdelloses M, Gallego Pérez-Larraya J, Zalacaín M, Marrodán L, Varela-Guruceaga M, Laspidea V, Aristu JJ, Ramos LI, Tejada-Solís S, Díez-Valle R, Jones C, Mackay A, Martínez-Climent JA, García-Barchino MJ, Raabe E, Monje M, Becher OJ, Junier MP, El-Habr EA, Chneiweiss H, Aldave G, Jiang H, Fueyo J, Patiño-García A, Gomez-Manzano C, Alonso MM.

Nat Commun. 2019 May 28;10(1):2235. doi: 10.1038/s41467-019-10043-0.

2.

Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [18F]FDG and sodium [18F]fluoride PET.

Collantes M, Martínez-Vélez N, Zalacain M, Marrodán L, Ecay M, García-Velloso MJ, Alonso MM, Patiño-García A, Peñuelas I.

BMC Cancer. 2018 Nov 29;18(1):1193. doi: 10.1186/s12885-018-5122-y.

3.

SAR Studies Leading to the Identification of a Novel Series of Metallo-β-lactamase Inhibitors for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections That Display Efficacy in an Animal Infection Model.

Leiris S, Coelho A, Castandet J, Bayet M, Lozano C, Bougnon J, Bousquet J, Everett M, Lemonnier M, Sprynski N, Zalacain M, Pallin TD, Cramp MC, Jennings N, Raphy G, Jones MW, Pattipati R, Shankar B, Sivasubrahmanyam R, Soodhagani AK, Juventhala RR, Pottabathini N, Pothukanuri S, Benvenuti M, Pozzi C, Mangani S, De Luca F, Cerboni G, Docquier JD, Davies DT.

ACS Infect Dis. 2019 Jan 11;5(1):131-140. doi: 10.1021/acsinfecdis.8b00246. Epub 2018 Nov 30.

4.

Discovery of a Novel Metallo-β-Lactamase Inhibitor That Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae.

Everett M, Sprynski N, Coelho A, Castandet J, Bayet M, Bougnon J, Lozano C, Davies DT, Leiris S, Zalacain M, Morrissey I, Magnet S, Holden K, Warn P, De Luca F, Docquier JD, Lemonnier M.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00074-18. doi: 10.1128/AAC.00074-18. Print 2018 May.

5.

Reducing Antibacterial Development Risk for GSK1322322 by Exploring Potential Human Dose Regimens in Nonclinical Efficacy Studies Using Immunocompetent Rats.

Hoover JL, Singley CM, Elefante P, DeMarsh P, Zalacain M, Rittenhouse S.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00959-17. doi: 10.1128/AAC.00959-17. Print 2017 Nov.

6.

Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells.

González-Fernández Y, Imbuluzqueta E, Zalacain M, Mollinedo F, Patiño-García A, Blanco-Prieto MJ.

Cancer Lett. 2017 Mar 1;388:262-268. doi: 10.1016/j.canlet.2016.12.012. Epub 2016 Dec 18.

PMID:
27998763
7.

Pathogen Prevalence and Antimicrobial Susceptibility Among Enterobacteriaceae Causing Hospital-associated Intra-abdominal Infections in Adults in the United States (2012-2013).

Zalacain M, Biedenbach DJ, Badal RE, Young K, Motyl M, Sahm DF.

Clin Ther. 2016 Jun;38(6):1510-1521. doi: 10.1016/j.clinthera.2016.04.035. Epub 2016 May 24.

PMID:
27234360
8.

Matrix-Gla protein promotes osteosarcoma lung metastasis and associates with poor prognosis.

Zandueta C, Ormazábal C, Perurena N, Martínez-Canarias S, Zalacaín M, Julián MS, Grigoriadis AE, Valencia K, Campos-Laborie FJ, Rivas Jde L, Vicent S, Patiño-García A, Lecanda F.

J Pathol. 2016 Aug;239(4):438-49. doi: 10.1002/path.4740. Epub 2016 Jun 29.

PMID:
27172275
9.

The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.

Martínez-Vélez N, Xipell E, Vera B, Acanda de la Rocha A, Zalacain M, Marrodán L, Gonzalez-Huarriz M, Toledo G, Cascallo M, Alemany R, Patiño A, Alonso MM.

Clin Cancer Res. 2016 May 1;22(9):2217-25. doi: 10.1158/1078-0432.CCR-15-1899. Epub 2015 Nov 24.

10.

Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.

Hoover J, Lewandowski T, Straub RJ, Novick SJ, DeMarsh P, Aubart K, Rittenhouse S, Zalacain M.

Antimicrob Agents Chemother. 2015 Oct 19;60(1):180-9. doi: 10.1128/AAC.01842-15. Print 2016 Jan.

11.

Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.

Fernández L, Valentín J, Zalacain M, Leung W, Patiño-García A, Pérez-Martínez A.

Cancer Lett. 2015 Nov 1;368(1):54-63. doi: 10.1016/j.canlet.2015.07.042. Epub 2015 Aug 11.

PMID:
26276724
12.

Frequency of Spontaneous Resistance to Peptide Deformylase Inhibitor GSK1322322 in Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae.

Min S, Ingraham K, Huang J, McCloskey L, Rilling S, Windau A, Pizzollo J, Butler D, Aubart K, Miller LA, Zalacain M, Holmes DJ, O'Dwyer K.

Antimicrob Agents Chemother. 2015 Aug;59(8):4644-52. doi: 10.1128/AAC.00484-15. Epub 2015 May 26.

13.

The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity.

Martinez-Velez N, Xipell E, Jauregui P, Zalacain M, Marrodan L, Zandueta C, Vera B, Urquiza L, Sierrasesúmaga L, Julián MS, Toledo G, Fueyo J, Gomez-Manzano C, Torre W, Lecanda F, Patiño-García A, Alonso MM.

J Bone Miner Res. 2014 Oct;29(10):2287-96. doi: 10.1002/jbmr.2253.

14.

Potent sub-MIC effect of GSK1322322 and other peptide deformylase inhibitors on in vitro growth of Staphylococcus aureus.

Butler D, Chen D, O'Dwyer K, Lewandowski T, Aubart K, Zalacain M.

Antimicrob Agents Chemother. 2014;58(1):290-6. doi: 10.1128/AAC.01292-13. Epub 2013 Oct 28.

15.

Staphylococcus aureus formyl-methionyl transferase mutants demonstrate reduced virulence factor production and pathogenicity.

Lewandowski T, Huang J, Fan F, Rogers S, Gentry D, Holland R, Demarsh P, Aubart K, Zalacain M.

Antimicrob Agents Chemother. 2013 Jul;57(7):2929-36. doi: 10.1128/AAC.00162-13. Epub 2013 Apr 9.

16.

Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322.

O'Dwyer K, Hackel M, Hightower S, Hoban D, Bouchillon S, Qin D, Aubart K, Zalacain M, Butler D.

Antimicrob Agents Chemother. 2013 May;57(5):2333-42. doi: 10.1128/AAC.02566-12. Epub 2013 Mar 11.

17.

Cortactin (CTTN) overexpression in osteosarcoma correlates with advanced stage and reduced survival.

Folio C, Zalacain M, Zandueta C, Ormazábal C, Sierrasesúmaga L, San Julián M, de las Rivas J, Toledo G, Lecanda F, Patiño-García A.

Cancer Biomark. 2011-2012;10(1):35-41. doi: 10.3233/CBM-2012-0227.

PMID:
22297550
18.

Understanding the origins of time-dependent inhibition by polypeptide deformylase inhibitors.

Totoritis R, Duraiswami C, Taylor AN, Kerrigan JJ, Campobasso N, Smith KJ, Ward P, King BW, Murrayz-Thompson M, Jones AD, Van Aller GS, Aubart KM, Zalacain M, Thrall SH, Meek TD, Schwartz B.

Biochemistry. 2011 Aug 9;50(31):6642-54. doi: 10.1021/bi200655g.

PMID:
21711014
19.

Catalytic asymmetric synthesis of γ-substituted vinyl sulfones.

López R, Zalacain M, Palomo C.

Chemistry. 2011 Feb 18;17(8):2450-7. doi: 10.1002/chem.201003177. Epub 2011 Jan 19.

PMID:
21254268
20.

A rapid microtiter plate assay for measuring the effect of compounds on Staphylococcus aureus membrane potential.

Gentry DR, Wilding I, Johnson JM, Chen D, Remlinger K, Richards C, Neill S, Zalacain M, Rittenhouse SF, Gwynn MN.

J Microbiol Methods. 2010 Nov;83(2):254-6. doi: 10.1016/j.mimet.2010.08.012. Epub 2010 Aug 27.

PMID:
20801170
21.

Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

Patiño-García A, Zalacain M, Folio C, Zandueta C, Sierrasesúmaga L, San Julián M, Toledo G, De Las Rivas J, Lecanda F.

Clin Cancer Res. 2009 Aug 15;15(16):5082-91. doi: 10.1158/1078-0432.CCR-09-0300. Epub 2009 Aug 11.

22.

Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets.

Folio C, Mora MI, Zalacain M, Corrales FJ, Segura V, Sierrasesúmaga L, Toledo G, San-Julián M, Patiño-García A.

J Proteome Res. 2009 Aug;8(8):3882-8. doi: 10.1021/pr900113w.

PMID:
19492781
23.

Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.

Patiño-García A, Zalacaín M, Marrodán L, San-Julián M, Sierrasesúmaga L.

J Pediatr. 2009 May;154(5):688-93. doi: 10.1016/j.jpeds.2008.11.030. Epub 2009 Jan 21.

24.
25.

Selection of retapamulin, a novel pleuromutilin for topical use.

Rittenhouse S, Biswas S, Broskey J, McCloskey L, Moore T, Vasey S, West J, Zalacain M, Zonis R, Payne D.

Antimicrob Agents Chemother. 2006 Nov;50(11):3882-5.

26.

Effects of benzopyrene-7,8-diol-9,10-epoxide (BPDE) in vitro and of maternal smoking in vivo on micronuclei frequencies in fetal cord blood.

Zalacain M, Sierrasesumaga L, Larrañnaga C, Patiñno-García A.

Pediatr Res. 2006 Aug;60(2):180-4.

PMID:
16864700
27.

Phylogenomic and biochemical characterization of three Legionella pneumophila polypeptide deformylases.

Huang J, Van Aller GS, Taylor AN, Kerrigan JJ, Liu WS, Trulli JM, Lai Z, Holmes D, Aubart KM, Brown JR, Zalacain M.

J Bacteriol. 2006 Jul;188(14):5249-57.

28.

Peptide deformylase inhibitors.

Aubart K, Zalacain M.

Prog Med Chem. 2006;44:109-43. Review. No abstract available.

PMID:
16697896
29.

ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia.

Agirre X, Román-Gómez J, Jiménez-Velasco A, Garate L, Montiel-Duarte C, Navarro G, Vázquez I, Zalacain M, Calasanz MJ, Heiniger A, Torres A, Minna JD, Prósper F.

Oncogene. 2006 Mar 23;25(13):1862-70. Erratum in: Oncogene. 2013 Feb 7;32(6):803.

PMID:
16314841
30.

[The cytogenetic assay as a measure of genetic instability induced by genotoxic agents].

Zalacain M, Sierrasesúmaga L, Patiño A.

An Sist Sanit Navar. 2005 May-Aug;28(2):227-36. Review. Spanish.

31.

Mechanism of time-dependent inhibition of polypeptide deformylase by actinonin.

Van Aller GS, Nandigama R, Petit CM, DeWolf WE Jr, Quinn CJ, Aubart KM, Zalacain M, Christensen SB, Copeland RA, Lai Z.

Biochemistry. 2005 Jan 11;44(1):253-60.

PMID:
15628866
32.

Characterization of Streptococcus pneumoniae TrmD, a tRNA methyltransferase essential for growth.

O'Dwyer K, Watts JM, Biswas S, Ambrad J, Barber M, Brulé H, Petit C, Holmes DJ, Zalacain M, Holmes WM.

J Bacteriol. 2004 Apr;186(8):2346-54.

33.

A global approach to identify novel broad-spectrum antibacterial targets among proteins of unknown function.

Zalacain M, Biswas S, Ingraham KA, Ambrad J, Bryant A, Chalker AF, Iordanescu S, Fan J, Fan F, Lunsford RD, O'Dwyer K, Palmer LM, So C, Sylvester D, Volker C, Warren P, McDevitt D, Brown JR, Holmes DJ, Burnham MK.

J Mol Microbiol Biotechnol. 2003;6(2):109-26.

PMID:
15044829
34.

Insights into catalysis by a knotted TrmD tRNA methyltransferase.

Elkins PA, Watts JM, Zalacain M, van Thiel A, Vitazka PR, Redlak M, Andraos-Selim C, Rastinejad F, Holmes WM.

J Mol Biol. 2003 Nov 7;333(5):931-49.

PMID:
14583191
35.

Inhibitors of pantothenate kinase: novel antibiotics for staphylococcal infections.

Choudhry AE, Mandichak TL, Broskey JP, Egolf RW, Kinsland C, Begley TP, Seefeld MA, Ku TW, Brown JR, Zalacain M, Ratnam K.

Antimicrob Agents Chemother. 2003 Jun;47(6):2051-5.

36.

The promoter of a cold-shock-like gene has pleiotropic effects on Streptomyces antibiotic biosynthesis.

Martínez-Costa OH, Zalacaín M, Holmes DJ, Malpartida F.

FEMS Microbiol Lett. 2003 Mar 28;220(2):215-21.

37.

Characterization of a novel fucose-regulated promoter (PfcsK) suitable for gene essentiality and antibacterial mode-of-action studies in Streptococcus pneumoniae.

Chan PF, O'Dwyer KM, Palmer LM, Ambrad JD, Ingraham KA, So C, Lonetto MA, Biswas S, Rosenberg M, Holmes DJ, Zalacain M.

J Bacteriol. 2003 Mar;185(6):2051-8.

38.

Novel antibacterials: a genomics approach to drug discovery.

Chan PF, Macarron R, Payne DJ, Zalacain M, Holmes DJ.

Curr Drug Targets Infect Disord. 2002 Dec;2(4):291-308. Review.

PMID:
12570737
39.

Genetic characterization of gram-positive homologs of the XerCD site-specific recombinases.

Chalker AF, Lupas A, Ingraham K, So CY, Lunsford RD, Li T, Bryant A, Holmes DJ, Marra A, Pearson SC, Ray J, Burnham MK, Palmer LM, Biswas S, Zalacain M.

J Mol Microbiol Biotechnol. 2000 Apr;2(2):225-33.

PMID:
10939248
40.

Transcriptional attenuation control of the tylosin-resistance gene tlrA in Streptomyces fradiae.

Kelemen GH, Zalacain M, Culebras E, Seno ET, Cundliffe E.

Mol Microbiol. 1994 Nov;14(4):833-42.

PMID:
7534372
42.
44.

Inducible ribosomal RNA methylation in Streptomyces lividans, conferring resistance to lincomycin.

Jenkins G, Zalacain M, Cundliffe E.

J Gen Microbiol. 1989 Dec;135(12):3281-8.

PMID:
2483994
45.
46.

Molecular analysis of the pac gene encoding a puromycin N-acetyl transferase from Streptomyces alboniger.

Lacalle RA, Pulido D, Vara J, Zalacaín M, Jiménez A.

Gene. 1989 Jul 15;79(2):375-80.

PMID:
2676728
47.

Similar short elements in the 5' regions of the STA2 and SGA genes from Saccharomyces cerevisiae.

Pardo JM, Iáñez E, Zalacaín M, Claros MG, Jiménez A.

FEBS Lett. 1988 Nov 7;239(2):179-84.

48.

The hyg gene promoter from Streptomyces hygroscopicus: a novel form of Streptomyces promoters.

Pulido D, Zalacaín M, Jiménez A.

Biochem Biophys Res Commun. 1988 Feb 29;151(1):270-4.

PMID:
2831883
49.

Purification and characterization of a hygromycin B phosphotransferase from Streptomyces hygroscopicus.

Zalacain M, Pardo JM, Jiménez A.

Eur J Biochem. 1987 Jan 15;162(2):419-22.

50.

Cloning and expression in Escherichia coli of a hygromycin B phosphotransferase gene from Streptomyces hygroscopicus.

Zalacain M, Malpartida F, Pulido D, Jiménez A.

Eur J Biochem. 1987 Jan 15;162(2):413-8.

Supplemental Content

Loading ...
Support Center